- Home
- ATHA vs FCUV Comparison
ATHA vs FCUV Comparison
Compare ATHA & FCUV Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ATHA
- FCUV
- Stock Information
- Founded
- ATHA 2011
- FCUV 2012
- Country
- ATHA United States
- FCUV United States
- Employees
- ATHA N/A
- FCUV N/A
- Industry
- ATHA Medicinal Chemicals and Botanical Products
- FCUV Industrial Machinery/Components
- Sector
- ATHA Health Care
- FCUV Industrials
- Exchange
- ATHA Nasdaq
- FCUV Nasdaq
- Market Cap
- ATHA 14.8M
- FCUV 16.7M
- IPO Year
- ATHA 2020
- FCUV N/A
- Fundamental
- Price
- ATHA $0.40
- FCUV $1.94
- Analyst Decision
- ATHA Hold
- FCUV
- Analyst Count
- ATHA 3
- FCUV 0
- Target Price
- ATHA $0.50
- FCUV N/A
- AVG Volume (30 Days)
- ATHA 133.3K
- FCUV 21.9K
- Earning Date
- ATHA 08-07-2025
- FCUV 08-12-2025
- Dividend Yield
- ATHA N/A
- FCUV N/A
- EPS Growth
- ATHA N/A
- FCUV N/A
- EPS
- ATHA N/A
- FCUV N/A
- Revenue
- ATHA N/A
- FCUV $432,983.00
- Revenue This Year
- ATHA N/A
- FCUV N/A
- Revenue Next Year
- ATHA N/A
- FCUV N/A
- P/E Ratio
- ATHA N/A
- FCUV N/A
- Revenue Growth
- ATHA N/A
- FCUV 140.82
- 52 Week Low
- ATHA $0.22
- FCUV $1.69
- 52 Week High
- ATHA $3.51
- FCUV $10.90
- Technical
- Relative Strength Index (RSI)
- ATHA 53.29
- FCUV 31.55
- Support Level
- ATHA $0.38
- FCUV $1.87
- Resistance Level
- ATHA $0.41
- FCUV $2.23
- Average True Range (ATR)
- ATHA 0.02
- FCUV 0.18
- MACD
- ATHA -0.00
- FCUV 0.01
- Stochastic Oscillator
- ATHA 71.70
- FCUV 10.01
About ATHA Athira Pharma Inc.
Athira Pharma Inc is a late clinical-stage biopharmaceutical company focused on developing small molecules engineered to restore neuronal health and slow neurodegeneration. Its pipeline candidates are; Fosgonimeton (ATH-1017) is a small molecule drug candidate designed to enhance the activity of the neurotrophic hepatocyte growth factor (HGF) system; ATH-1020 a novel, orally available, next-generation small molecule drug candidate designed to positively modulate the neurotrophic HGF system; ATH-1105 is a novel, orally available, next-generation, small molecule drug candidate designed to positively modulate the neurotrophic HGF system.
About FCUV Focus Universal Inc.
Focus Universal Inc offers smart devices, IoT products, and patented products and technologies for 5G telecommunications and network security. It is focused on commercializing its universal smart technology and financial reporting software. Its product line includes various digital, analog, and quantum light meters and filtration products, the Ubiquitor universal smart device, SEC Financial Reporting Software, and other smart devices and sensors. The company's reportable segments are Corporate and IoT, which derives maximum revenue, and Perfecular and Lusher. The Corporate and IoT segment includes its LED and IoT installation and management business (under Smart AVX), specializing in LED and display systems, home theaters, lighting control, automation, and integration.